Healthcare: Is Amarin's Fish Oil Pill On Track To Become a Blockbuster? Plus, How Gene Editing Company CRISPR Therapeutics Just Took A Big Step Forward

Industry Focus

The Motley Fool

Interview, Money, Consumergoods, Business, Businessnews, Ceo, Technology, Investing, Stocks, Energy, Fool, Financial, Economy, Healthcare, News, Banking, Motley, Tech, Business News, Investments

4.6 • 854 Ratings

🗓️ 20 November 2019

⏱️ 24 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Amarin's shares rocketed higher after a key FDA committee recommended expanding the label of its triglycerides lowering drug, Vascepa, to include data showing it can reduce the risk of heart attack and stroke. Meanwhile, shares in CRISPR Therapeutics and partner Vertex Pharmaceuticals are also soaring following the release of interim, early-stage results for its gene-editing therapy for beta thalassemia and sickle cell disease therapy. Stocks: AMRN, CRSP, VRTX

Check out more of our content here:

Transcript

Click on a timestamp to play from that location

0:00.0	Thanks to Audible for supporting industry focus.
0:03.2	For a limited time, get three months of Audible
0:05.8	for $6.95 a month.
0:08.8	Choose one audiobook and two Audible originals for free.
0:12.4	Visit audible.com slash fool, or text fool to 500, 500.
0:21.2	Welcome to Industry Focus, the show that dives into a different sector of the stock market every single day.
0:27.0	Today is Wednesday, November the 20th, and we're talking health care.
0:31.0	I'm your host, Shannon Shannon Jones and I am joined by
0:33.7	health care guru Todd Campbell. Todd how's it going? Hi Shan glad to be here
0:38.1	looking forward to a really good show and wondering where the heck fall when I swear I blinked and it's all of a sudden it's
0:45.8	gone up here in New Hampshire and I guess that's just the way it goes.
0:49.2	That's just the way it goes because same thing here literally had no fall it went from being summer to middle of the
0:55.4	winter here so I feel your pain and I love the fall but what I really love though is
1:00.1	that the bio-pharma newsferie has been very kind to us Todd.
1:04.8	Matter of fact, we've got two just awesome updates that have come out of the Bio Pharma
1:10.8	space.
1:11.8	So I want to dive right in, the first of which
1:13.8	is one we've actually gotten a lot of listener questions
1:15.8	about on Twitter people have been asking about this.
1:18.4	But it's none other than Amaran, that's ticker symbol AMRN. Amaran.
1:24.0	Amaran, known for its drug Vassipa.
1:27.0	It's a basically a prescription strength fish oil pill.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.